Transitions in PAH Therapy

To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.

Step Status
Video/Document(s)
Posttest
Evaluation
Starts On: 7/1/2020: 12:00 AM
Ends On: 6/30/2021: 12:00 AM
Session Type: Internet Activity Enduring Material
Credits: 0.5
Description:

Faculty

Murali M. Chakinala, MD, FCCP
Professor of Medicine, Washington University School of Medicine
Director, WUSM & BJH Pulmonary HTN Care Center
Co-Director, WUSM HHT Center of Excellence
Financial Relationships:
Consulting/Advisory Committees: Actelion Pharmaceuticals, Akros Pharma, Inc., Arena Pharmaceuticals, Bayer AG, Express Scripts Inc., Phase Bio, Reata Pharmaceuticals, Trio Health Analytics, United Therapeutics
Speakers Bureau/Honoraria: Bayer AG, Gilead Sciences, Mentor Planning & Consulting, Simply Speaking, WebMD, LLC
Other: Pulmonary Hypertension Association

Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Midwest Pulmonary Vascular Symposium, September 28, 2019, which was supported in part by Bayer, United Therapeutics Corporation, Actelion Pharmaceuticals US, Inc. and Pfizer, Inc.

Planning Committee

Murali M. Chakinala, MD, FCCP
Professor of Medicine, Washington University School of Medicine
Director, WUSM & BJH Pulmonary HTN Care Center
Co-Director, WUSM HHT Center of Excellence
Financial Relationships:
Consulting/Advisory Committees: Actelion Pharmaceuticals, Akros Pharma, Inc., Arena Pharmaceuticals, Bayer AG, Express Scripts Inc., Phase Bio, Reata Pharmaceuticals, Trio Health Analytics, United Therapeutics
Speakers Bureau/Honoraria: Bayer AG, Gilead Sciences, Mentor Planning & Consulting, Simply Speaking, WebMD, LLC
Other: Pulmonary Hypertension Association

Keith A. Fester, PharmD, MHA, BCPS
Clinical Pharmacy Specialist; Lung Transplantation and Pulmonary Hypertension
Financial Relationships: Nothing to disclose

Colleen McEvoy, MD
Assistant Professor of Medicine
Financial Relationships:
Consulting/Advisory Committees: Actelion Pharmaceuticals
Speakers Bureau/Honoraria: Actelion Pharmaceuticals
Research Support/Grants: Actelion Ltd.

Lewis G. Satterwhite, MD
Associate Professor of Medicine, Division of Pulmonary & Critical Care Medicine
Medical Director - Medical Intensive Care Units; The University of Kansas Medical Center, Kansas City, Kansas
Financial Relationships: Nothing to disclose

Leslie A. Spikes, MD
Assistant Professor of Medicine, Division of Pulmonary & Critical Care Medicine
The University of Kansas Medical Center, Kansas City, Kansas
Financial Relationships: Nothing to disclose

Timothy L. Williamson, MD, FCCP
Associate Professor of Medicine, Division of Pulmonary & Critical Care Medicine
Director, Pulmonary Vascular Center, The University of Kansas Medical Center, Kansas City, Kansas
Financial Relationships: Nothing to disclose
Objectives: The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
  • Summarize indications for transitioning between therapies for PAH.
  • Determine the need to "step-up" therapy for patients not meeting comprehensive treatment goals.
  • Appreciate unique pharmacologic aspects different prostacyclin pathway activators.
  • Apply pre-transition criteria for safely "stepping down" in therapy.
  • Describe how to determine success after transition.
Additional Information:
Target Audience: This course is designed for pulmonologists, intensivists, cardiologists, rheumatologists, internists, critical care physicians, primary care, nurses, nurse practitioners, physician assistants, pharmacists and other health professionals.

Publication Date: July 1, 2020
Expiration Date: June 30, 2021
Accreditation Information:
wustlcme
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
References:
  • Gomberg-Maitland M. Am J Respir Crit Care Med. 2005;172:1586-1589.
  • Frost AE. J Heart Lung Transplant. 2019; 38(1)
  • Chakinala MM. J Heart Lung Transplant. 2017; 36(2)
  • Maestas T. Pulm Circ. 2018; 8(4)
  • Humbert M. N Engl J Med. 2004;351:1425-1436
  • Hoeper, MM. Eur Resp J. 2017; 50(3)
Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.

Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Categories: Cardiology, Pulmonology


Powered By AI 4.5